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Abstract 
Objectives: Local, abdominal fat depots may be related to alterations in cardiac function and morphology due to 
a metabolic linkage. Thus, we aimed to determine their association with subtle cardiac changes and the potential 
interaction with hyperglycemic metabolic states.
Methods: Subjects from the general population and without history of cardiovascular disease were drawn from the 
Cooperative Health Research in the Region of Augsburg FF4 cohort and underwent 3 T cardiac and body MRI. Meas-
ures of abdominal adiposity such as hepatic proton-density fat fraction  [PDFFhepatic], subcutaneous (SAT) and visceral 
abdominal fat (VAT) as well as established cardiac left-ventricular (LV) measures including LV remodeling index (LVCI) 
were derived. Associations were determined using linear regression analysis based on standard deviation normalized 
predictors.
Results: Among a total of 374 subjects (56.2 ± 9.1 years, 58% males), 49 subjects had diabetes, 99 subjects had pre-
diabetes and 226 represented normal controls. Only subtle cardiac alterations were observed (e.g. LVCI: 1.13 ± 0.30). 
While SAT was not associated, increasing VAT and increasing  PDFFhepatic were independently associated with increas-
ing LVCI (β = 0.11 and 0.06, respectively), decreasing LV end-diastolic volume (β = − 6.70 and 3.23, respectively), and 
decreasing LV stroke volume (β = − 3.91 and − 2.20, respectively). Hyperglycemic state did not modify the associa-
tions between VAT or PDFF and LV measures (interaction term: all p ≥ 0.29).
Conclusion: In a healthy population, VAT but also  PDFFhepatic were associated with subclinical measures of LV remod-
eling without evidence for a modifying effect of hyperglycemic state.
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Introduction
Diabetes, particular type-2 diabetes, threatens the 
health of a large number of individuals and is associ-
ated with worse prognosis, mainly because of increased 
risk for adverse cardiovascular events [1, 2]. Beside 
patients with manifest diabetes, there is a relevant 
number of patients with impaired glucose metabolism 
who do not satisfy diabetes criteria, and who are con-
sidered as pre-diabetics since they often progress into 
type-2 diabetes and have a higher risk of cardiovascular 
events [3, 4]. Thus, risk assessment is a crucial objective 
in this cohort in order to identify patients who could 
benefit from prevention.
A potential risk marker as well pathophysiological 
interlink are local fat depots such as visceral abdominal 
fat adipose tissue (VAT) or hepatic steatosis given step-
wise higher levels between normal, pre-diabetic and 
diabetic patients [5]. Beside storage of lipids, adipose 
tissue has pro-inflammatory characteristics by secreting 
cytokines [6, 7]. However, epidemiological evidence dem-
onstrated that VAT and not subcutaneous adipose tissue 
(SAT) was specifically associated with cardiovascular 
risk factors and coronary heart disease [8]. Also evidence 
from previous studies indicated that VAT was associ-
ated with left-ventricular (LV) morphology and/or func-
tion [9–19], often superior and/or independently of SAT 
or body mass index (BMI) [17, 18]. This was shown in 
non-diabetic patients by Rider et al. [10] where an inde-
pendent association of increased VAT with decreased LV 
function was observed. Neeland et al. [11] demonstrated 
a correlation of VAT and LV morphology in obese and 
non-obese patients independently of the diabetes status. 
A sub-study of the MESA cohort including 4364 subjects, 
both insulin resistance and waist-to-hip-ratio (WHR)—a 
rough surrogate for VAT, were associated with concentric 
LV remodeling, a precursor to heart failure, both inde-
pendent of BMI [13]. In a smaller subgroup of the MESA 
study with available abdominal CT scan, direct measures 
of VAT by CT were also associated with concentric LV 
remodeling [14]. Park et  al. [15] pointed out an inde-
pendent and synergistic association of VAT and skeletal 
muscle mass on LV mass and function in a Korean cohort 
study and noted that study participants with insulin 
resistance had more VAT. Given the potential association 
of local fat depots, particular VAT, to LV remodeling but 
also to diabetes [20], an influence of the diabetic status 
on the association between VAT and LV remodeling is 
suggestive and needs to be further examined.
Thus, our primary aim was to study the association of 
VAT with measures of LV morphology and function in a 
population free of previously known cardiovascular dis-
ease, potentially independent of cardiovascular risk fac-
tors and other measurements of obesity. Our secondary 
aim was to determine whether these associations are 
affected by hyperglycemic metabolic state.
Methods
Study design and population
The study was designed as a case–control study nested 
in a prospective cohort from the “Cooperative Health 
Research in the Region of Augsburg” (KORA) in which 
subjects with diabetes, with prediabetes and controls 
recruited from the FF4 follow-up of the KORA S4 study 
underwent whole-body MR imaging. The study design, 
sampling method and data collection are described in 
detail elsewhere [5, 21]. Briefly, subjects were excluded 
if there was history of cardiovascular disease defined as 
validated/self-reported stroke, myocardial infarction or 
revascularization. In addition, subjects with non-MRI 
safe devices including e.g. cardiac pacemaker or implant-
able defibrillator, report of cerebral aneurysm clip or 
serum creatinine ≥ 1.3 mg/dL were excluded.
The study was approved by the institutional review 
board of the medical faculty of Ludwig-Maximilian Uni-
versity Munich and all participants provided written 
informed consent.
Health assessment
Subjects of the KORA S4 cohort were re-examined 
between June 2013 and September 2014 at the KORA 
study center. An oral glucose tolerance test was admin-
istered to all participants who had not been diagnosed 
for type-2 diabetes. For the definition of pre-diabetes, the 
1998 World Health Organization criteria were applied 
[22]. Subjects with prediabetes had an impaired glucose 
tolerance (IGT) as defined by a normal fasting glucose 
concentration and a 2-h serum glucose concentration 
measured by oral glucose tolerance test (OGTT) ranging 
between 140 and 200 mg/dL and/or impaired fasting glu-
cose (IFG), as defined by a fasting glucose level between 
110 and 125 mg/dL and a normal 2-h serum glucose con-
centration. Individuals with a 2-h serum glucose con-
centration measured by OGTT above 200  mg/dL and/
or a fasting glucose level above 125  mg/dL were classi-
fied as newly diagnosed diabetics. Subjects with normal 
glucose metabolism with a 2-h serum glucose concentra-
tion measured by OGTT below 140 mg/dL and a fasting 
glucose level below 110 mg/dL were classified as normal 
controls.
Other established risk factors were collected in stand-
ardized fashion as part of the KORA study design and 
described elsewhere [5]. Briefly, hypertension was 
defined as systolic blood pressure of at least 140 mmHg 
or diastolic blood pressure of at least 90 mmHg or cur-
rent antihypertensive treatment. Subjects were classi-
fied as smokers if they had smoked at least one cigarette 
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per day in the year prior to the study. BMI was defined 
as weight (kg) divided by the height squared  (m2). Medi-
cations were assigned as ‘antihypertensive medication’ 
only if the compounds taken were classified as antihy-
pertensively effective by the most recent guidelines. 
Antithrombotic medication comprised anticoagulants 
and antiplatelet drugs. Lipid lowering medication was 
defined as treatment with statins, fibrates or other lipid 
modifying agents.
Magnetic resonance imaging
MR images were acquired using a 3 T Magnetom Skyra 
(Siemens AG, Healthcare Sector, Erlangen Germany) 
equipped with a whole-body coiling system. All subjects 
underwent the imaging protocol within 3  months after 
the visit at the study center. The whole-body protocol is 
described in detail elsewhere [5]. All image analyses were 
performed in blinded fashion by independent readers 
unaware of the diabetic status and clinical covariates on 
dedicated off-line workstations.
Assessment of abdominal adipose tissue by magnetic 
resonance imaging
VAT and SAT were estimated at the umbilical level on 
a single axial slice since this approach is representative 
for the total amount of abdominal adipose tissue [23]. 
The amount of abdominal fat was measured on an axial 
reconstructed 3D VIBE-Dixon image (5 mm slice thick-
ness) in  cm2 and segmented by an automated procedure 
based on fuzzy-clustering [24].
Assessment of hepatic lipids by magnetic resonance 
imaging
For determination of hepatic lipid content, a multi-echo 
Dixon-VIBE sequence was used with 6  T (1.23, 2.46, 
3.69, 4.92, 6.15, 7.38  ms) accounting for T2* decay and 
the spectral complexity of fat (slice thickness 4 mm) [25, 
26]. Using OsiriX (Version 4.1), a manual region of inter-
est was drawn at the level of the portal vein excluding the 
hilus and large vessels for estimation of Pearson’s correla-
tion coefficients [5].
Assessment of cardiac function and morphology 
by magnetic resonance imaging
The cine-SSFP sequences were evaluated semi-automat-
ically using commercially available software (cvi42, Cir-
cle Cardiovascular Imaging, Calgary, Canada). Following 
automatic contour detection of the LV endocardium, all 
borders were corrected manually, if necessary. LV myo-
cardial mass (LVM), LV end-diastolic volume (LVEDV), 
LV end-systolic volume (LVESV) and ejection fraction 
(LVEF) were derived accordingly to current guidelines 
[27]. LV concentricity index (LVCI) was calculated as 
‘LVM/LVEDV’, an abnormal increased LVCI was defined 
> 1.3  g/mL [28]. LV stroke volume (LVSV) was calcu-
lated as ‘LVEDV–LVESV’. The parameters LVM, LVEDV, 
LVESV, and LVSV are indexed based on body surface 
area (BSA) for all analyses. LV hypertrophy was defined 
increased LVM (≥ 96  g/m2 [women] and ≥ 116  g/m2 
[men]) [29]; eccentric vs. concentric LV hypertrophy was 
based on an abnormal LVCI.
Statistical analysis
Subject demographics, cardiovascular risk factors and 
MR outcomes are presented for the overall study sam-
ple and according to VAT tertiles as means and stand-
ard deviations for continuous variables and counts and 
percentages for categorical variables. Measurement dif-
ferences among VAT tertiles were evaluated by one-way 
ANOVA and χ2 test, respectively. Correlations between 
abdominal fat and LV measures were displayed by scat-
ter plots and Pearson’s correlation coefficients were 
provided.
Associations of abdominal fat with LVM, LVCI, LVEDV 
and LVSV were assessed by separate linear regression 
models with β-coefficients and 95% confidence inter-
vals (CI). Abdominal fat parameters were modelled as 
standard deviation increments. Regression models were 
adjusted (a) for age and sex, (b) for age, sex and BMI and 
(c) fully. For the fully adjusted model, covariates beyond 
age, sex and BMI were selected based on univariate anal-
ysis (Appendix Table 4; all with p < 0.10); the fully model 
included hypertension, diabetes, triglycerides, HDL (for 
all LV parameters), additionally LDL (for LVCI, LVEDV, 
and LVSV) and lipid lowering medication (for LVM, and 
LVCI). As a sensitivity analysis, the fully adjusted models 
were repeated with a fixed set of typical cardiovascular 
risk factors (including age, sex, BMI, hypertension, dia-
betes, and smoking status) and with a fixed set of typi-
cal cardiovascular risk factors replacing the definition 
of hypertension by actual measures of systolic and dias-
tolic blood pressure and the presence of antihypertensive 
medication (including age, sex, BMI, systolic blood pres-
sure, diastolic blood pressure, antihypertensive medica-
tion, diabetes, smoking).
Furthermore the conjoint associations of abdominal fat 
parameters with LVCI, LVEDV and LVSV were estimated 
by age, sex and BMI adjusted linear regression model. 
Forrest plots were drawn and model-fit was expressed by 
 R2.
A multiplicative interaction effect of diabetes sta-
tus (normal controls, prediabetic and diabetic subjects) 
on the association between VAT and LV measures was 
tested. In addition, associations between VAT and LV 
measures were separately analysed for the diabetes 
groups by age and sex adjusted linear regression models 
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and by boxplots of LVCI across tertiles of VAT including 
a trend test.
A p value of < 0.05 was considered to indicate statistical 
significance. All analyses were conducted with Stata 14.1 
(Stata Corporation, College Station, TX, USA).
Results
A total of 400 subjects without clinically known cardio-
vascular disease underwent MR imaging and complete 
VAT and LV measurements were available in 374 sub-
jects. Excluded subjects did not differ from the included 
subjects with respect to age, gender or diabetic status (all 
p ≥ 0.36). Of the final cohort (age 56.2 ± 9.1  years, 58% 
males), 49 subjects had diabetes, 99 subjects had pre-
diabetes and 226 represented normal controls. Based on 
MRI measurements, mean VAT was 147.31 ± 85.02  cm2 
with lower tertile from 11.06 to < 98.94  cm2, mid tertile 
from 98.94 to < 175.79 cm2 and upper tertile from 175.79 
to 456.36 cm2. Demographic and risk profiles—stratified 
by VAT tertiles—are provided in Table 1. VAT was highly 
interlinked with other measures of adiposity (Table 1).
LV morphology and function and its correlation 
with adiposity
Measures of LV morphology and function are provided 
in Table 1. In this low-risk population and based on the 
Table 1 Characteristics of the study sample according to VAT tertiles
Data are means and standard deviations for continuous variables and counts and percentages for categorical variables
RR blood pressure, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, PDFFhepatic hepatic proton-density fat fraction, LV left-ventricular
* p values are from one-way ANOVA and χ2 test, respectively
All subjects VAT—lower tertile VAT—mid tertile VAT—upper tertile p value*
N 374 124 125 125
Age (years) 56.2 ± 9.1 51.8 ± 7.8 57.0 ± 9.3 59.8 ± 8.3 < 0.001
Sex (men) 57.8% (216) 35.5% (44) 61.6% (77) 76.0% (95) < 0.001
BMI (kg/m2) 27.9 ± 4.8 24.2 ± 3.1 28.7 ± 4.1 30.9 ± 4.3 < 0.001
Diabetes status
 Normal 60.4% (226) 91.9% (114) 63.2% (79) 26.4% (33) < 0.001
 Prediabetes 26.5% (99) 6.5% (8) 28.8% (36) 44.0% (55)
 Diabetes 13.1% (49) 1.6% (2) 8.0% (10) 29.6% (37)
HbA1c 5.6 ± 0.7 5.3 ± 0.4 5.6 ± 0.9 5.8 ± 0.8 < 0.001
Hypertension 33.4% (125) 13.7% (17) 30.4% (38) 56.0% (70) < 0.001
Systolic RR (mmHg) 121 ± 17 110 ± 12 123 ± 16 129 ± 16 < 0.001
Diastolic RR (mmHg) 75 ± 10 70 ± 8 77 ± 10 79 ± 10 < 0.001
Antihypertensive medication 24.6% (92) 12.1% (15) 22.4% (28) 39.2% (49) < 0.001
Triglyceride levels (mg/dL) 130.5 ± 84.3 83.9 ± 38.9 132.2 ± 80.9 175.0 ± 95.6 < 0.001
Total cholesterol (mg/dL) 217.6 ± 36.4 207.8 ± 33.9 225.9 ± 36.4 219.1 ± 36.8 < 0.001
HDL (mg/dL) 62.0 ± 17.5 69.8 ± 19.3 61.6 ± 14.4 54.7 ± 15.1 < 0.001
LDL (mg/dL) 139.4 ± 33.0 129 ± 30.5 147.6 ± 31.4 141.4 ± 34.5 < 0.001
Lipid lowering medication 10.4% (39) 3.2% (4) 9.6% (12) 18.4% (23) < 0.001
Smoking status
 Never-smoker 36.1% (135) 41.9% (52) 36.0% (45) 30.4% (38) 0.03
 Ex-smoker 43.9% (164) 33.1% (41) 44.8% (56) 53.6% (67)
 Current-smoker 20.1% (75) 25.0% (31) 19.2% (24) 16.0% (20)
MRI-based adiposity measures
 VAT  (cm2) 147.31 ± 85.02 57.8 ± 23.23 139.77 ± 22.56 243.64 ± 57.22 N/A
 SAT  (cm2) 278.51 ± 117.44 210.00 ± 86.43 308.84 ± 119.13 316.73 ± 113.14 < 0.001
 PDFFhepatic (%) 8.4 ± 8.4 2.8 ± 2.3 7.0 ± 6.7 15.5 ± 8.9 < 0.001
MR-based LV measures
 LV mass, indexed (LVM; g/m2) 71.7 ± 13.9 67.0 ± 11.8 72.5 ± 15.2 75.6 ± 13.2 < 0.001
 LV concentricity index (LVCI; g/mL) 1.13 ± 0.30 0.94 ± 0.19 1.11 ± 0.23 1.33 ± 0.33 < 0.001
 LV end-diastolic volume, indexed (LVEDV; mL/m2) 66.20 ± 14.87 72.52 ± 13.41 66.82 ± 13.65 59.3 ± 14.56 < 0.001
 LV ejection fraction (LVEF; %) 69.2 ± 8.2 68.5 ± 8.6 69.4 ± 7.3 69.6 ± 8.6 0.53
 LV stroke volume, indexed (LVSV; mL/m2) 45.4 ± 9.7 49.4 ± 9.6 45.9 ± 8.5 40.8 ± 9.0 < 0.001
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MRI-based LVM measurements, LV hypertrophy was 
observed in four subjects—two with concentric and two 
with eccentric remodeling. In addition, three subjects 
had increased LVCI levels with normal LVM.
A stepwise increase was observed for LVM and LVCI 
across tertiles of VAT, while VAT decreased for LVEDV 
and LVSV (Table  1). LVEF was not different between 
VAT tertiles. Correlations between LV measures and 
MR-measures of adiposity are illustrated in Fig. 1; inter-
estingly while for LVCI, LVEDV and LVSV all measures 
of adiposity were significantly correlated, only VAT was 
significantly correlated with LVM. Overall, strongest cor-
relation was between VAT and LVCI (r = 0.54, p < 0.0001).
Multivariable analysis of the association 
between abdominal adiposity and LV measures
The associations of VAT, SAT and  PDFFhepatic with LVM, 
which were observed in univariable analysis (Table  1), 
were attenuated after adjustment for age and gender (all 
p ≥ 0.21, Table  2). Further, none of the fat depots were 
associated with LVEF in any of the multivariate models 
(all p ≥ 0.14).
In contrast, the association of VAT and  PDFFhepatic with 
LVCI, LVEDV and LVSV persisted in all models adjust-
ing for all potential confounders (Table  2). While LVCI 
increased with increasing amount of fat, the associa-
tion of LVEDV and LVSV were inversely associated with 
abdominal fat. Comparing VAT and  PDFFhepatic in the 
association to LV measures, the effect size per standard 
deviation of VAT was larger than for  PDFFhepatic through-
out all LV measures and models.
Conversely, SAT was associated with LVCI and LVEDV 
in a basic model taking into account for age and gender, 
however attenuated by adjusting for BMI additionally. 
SAT and LVSV remained associated with LVDV also in a 
model including BMI and became borderline non-signif-
icant only in a fully adjusted model (p = 0.07). However, 
the effect size of SAT remained always below the effect 
size of  PDFFhepatic and even more below VAT (Table  2). 
These findings did not change substantially in sensitiv-
ity analysis for including different sets of potential con-
founders (Appendix Table 5).
In a model adjusting for age, gender, and BMI and all 
abdominal fat depots, both VAT and  PDFFhepatic provided 
Fig. 1 Correlation between abdominal fat depots and LV measures. Pearson’s correlation coefficients (r; together with p values) were provided for 
the correlation of the different fat depots including subcutaneous (SAT) and visceral (VAT) abdominal fat as well as  PDFFhepatic
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independent and incremental value of predicting LVCI, 
LVEDV and LVSV (Fig.  2). While these six variables 
resulted in an r-square of 0.21 and 0.23 for LVSV and 
LVEDV respectively, the r-square was 0.33 for LVCI.
Effect of the diabetic status on the observed associations
Assessing the association between VAT and LV measures 
in the subgroups of subjects with diabetes, prediabetes 
and controls, similar trends were observed as in the over-
all cohort, for example between VAT and LVCI (Fig. 3). 
The predefined interaction term to test whether the 
hyperglycemic metabolic status effects the association 
between VAT and LV measures was non-significant (all 
p ≥ 0.29; Table 3). Similarly, there was no effect modifica-
tion between HbA1c-Levels and the association between 
VAT and LV measures (all p ≥ 0.12).
Discussion
In this nested case–control MRI study from the prospec-
tive, population-based KORA cohort in subjects without 
history of cardiovascular disease, we observed an inde-
pendent association of VAT and  PDFFhepatic to LVCI, a 
measure of early LV remodeling, but also to LVEDV and 
LVSV, a potential indicator for diastolic dysfunction. In 
contrast, no independent association was observed for 
abdominal adiposity to LVM nor for SAT to any of the LV 
measures. Furthermore, hyperglycemic metabolic state 
did not modify the association between abdominal adi-
posity and LV measures.
Association of abdominal adiposity to LV remodeling
There is increasing evidence that abdominal adiposity is 
associated with worse metabolic state and cardiovascu-
lar complications [8]. Predominantly, this effect can be 
attributed to the amount of VAT as shown in a growing 
number of clinical and epidemiological studies, while 
SAT appears a more innocent bystander [11, 14, 15, 19, 
29]. Our results add to the growing body of data by con-
firming an independent association for VAT to measures 
of LV remodeling, but not for SAT. Thus, our results sup-
port previous findings on the highly relevant role of VAT 
and extend these to a relatively large western European 
population.
LV remodeling index as the ratio between LVM and 
LVEDV is an important MR-based cardiac measure 
representing a precursor of heart failure and worse out-
come [30]. Prior research by Abasi et  al. [14], which 
was derived from the MESA cohort, similarly observed 
increased LV remodeling indices in subjects with higher 
VAT level. In line with the MESA cohort, our cohort also 
excluded history of cardiovascular disease. Their find-
ing also demonstrates a subtle increase in LVCI, much 
smaller than observed in other studies, such as the Dal-
las heart study [11]. In a relatively small cohort of 75 
nondiabetic men, Granér et al. [19] showed that hepatic 
triglyceride as measured by MR spectroscopy and VAT 
were associated with dedicated, echocardiography based 
measures of LV diastolic dysfunction. Diastolic dysfunc-
tion caused by hypertrophy in which filling is impaired 
Table 2 Association of local abdominal fat depots with LV mass, volumes and function
Separated models were fit for VAT, SAT and  PDFFhepatic. β-coefficients represent change in LV parameters for standard deviation increment in abdominal fat 
measurements estimated by linear regression; a the fully adjusted model included age, sex, BMI, hypertension, diabetes, triglycerides, HDL (for all LV parameters), 
additionally LDL (for LVCI, LVEDV, and LVSV) and lipid lowering medication (for LVM, and LVCI). The selection of potential confounders for the fully adjusted model was 
done in univariate analyses for each of the different LV measurements (Appendix Table 4) to allow appropriate comparisons of the associations of the three fat depots 
to a particular LV measurement, but may limit the comparison between different LV measurements. To address this issue, sub-analyses were performed with a fixed 
set of common cardiovascular risk factors as potential confounders, no substantial differences were found (Appendix Table 5)
VAT visceral adipose tissue, SAT subcutaneous adipose tissue, PDFFhepatic hepatic proton-density fat fraction, LV left-ventricular, LVM left-ventricular mass (in g/m
2); LVCI 
left-ventricular concentricity index (in g/mL), LVEDV left-ventricular end-diastolic volume (in mL/m2), LVSC left ventricular stroke volume (in mL/m2)
LVM LVCI LVEDV LVSV
β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p
Separate models adjusted for age, sex
 VAT 0.78 (− 0.68; 2.23) 0.29 0.14 (0.11; 0.17) < 0.001 − 6.79 (− 8.36; − 5.21) < 0.001 − 4.26 (− 5.30; − 3.22) < 0.001
 SAT 0.83 (− 0.45; 2.10) 0.21 0.07 (0.04; 0.10) < 0.001 − 2.98 (− 4.45; -1.50) < 0.001 − 2.02 (− 2.99; − 1.05) < 0.001
 PDFFhepatic 0.37 (− 0.98; 1.71) 0.59 0.10 (0.07; 0.13) < 0.001 − 4.75 (− 6.26; − 3.24) < 0.001 − 3.15 (− 4.14; − 2.16) < 0.001
Separate models adjusted for age, sex, BMI
 VAT – 0.15 (0.11; 0.19) < 0.001 − 7.92 (− 9.93; − 5.91) < 0.001 − 4.8 (− 6.13; − 3.47) < 0.001
 SAT – 0.01 (− 0.05; 0.06) 0.83 − 1.69 (− 4.72; 1.34) 0.28 − 1.42 (− 3.41; 0.58) < 0.001
 PDFFhepatic – 0.09 (0.06; 0.12) < 0.001 − 4.43 (− 6.10; − 2.76) < 0.001 − 2.91 (− 4.00; − 1.81) < 0.001
Separate, fully adjusted  modelsa
 VAT – 0.11 (0.07; 0.15) < 0.001 − 6.70 (− 8.84; − 4.55) < 0.001 − 3.91 (− 5.32; − 2.50) < 0.001
 SAT – – – − 1.75 (− 3.66; 0.16) 0.07
 PDFFhepatic – 0.06 (0.02; 0.09) 0.001 − 3.23 (− 5.03; − 1.44) < 0.001 − 2.20 (− 3.37; − 1.04) < 0.001
Page 7 of 12Schlett et al. Cardiovasc Diabetol  (2018) 17:88 
due to low ventricular compliance may result in reduced 
LVEDV while both LVSV and LVEDV can be reduced 
without significant impact on LVEF. Accordingly, we 
found an association of abdominal adiposity with both, 
LVSV and LVEDV but not with LVEF, which may indicate 
that abdominal adiposity may affect more strongly the 
diastolic than systolic function in a first pathophysiologic 
step.
As described above, previous evidence on the asso-
ciation between hepatic steatosis and LV remodeling 
on a population-based cohort level is rare, given that 
most studies such as MESA or FHS employed CT to 
determine VAT and SAT and liver density in Houns-
field units by CT. However, CT represents only limited 
methods for assessment of adipose tissue content of 
the liver parenchyma [31] and it was only recently that 
rapid but robust and accurate multi-echo Dixon MR 
sequences became available [26]. As such, we demon-
strate that MR-based  PDFFhepatic is independently and 
incrementally associated with subtle changes of LV 
remodeling, particular beyond VAT and independent of 
diabetes.
Fig. 2 Forrest-plots of age-, gender- and BMI-adjusted model including VAT, SAT, and  PDFFhepatic for the Association to LVCI, LVEDV and LVSV. The 
model-fit of the different models expressed as r-square were 0.33, 0.23 and 0.21 for predicting LVCI, LVEDV and LVSV
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In a case–control study including 19 adults with type 2 
diabetes, 19 adults with non-alcoholic fatty liver disease 
(NAFLD) and 19 healthy controls, Dr. Cassidy et al. [32] 
showed that changes in cardiac structure are related with 
both, diabetes and NAFLD, even without overt cardiac 
disease and without changes in cardiac energy metabo-
lism. They postulated an interaction between NAFLD 
and diabetes with a two-hit hypothesis [32]. However, we 
couldn’t reveal any evidence for an interaction of diabetes 
with  PDFFhepatic regarding LV remodeling.
Beside overlapping risk factors for developing NAFLD 
and developing cardiovascular disease, there are several 
pathophysiological hypotheses of a more direct link-
age [33]. NAFLD is associated with an atherogenic lipid 
profile with e.g. the increased production of triglycer-
ide-rich very-low-density lipoprotein (VLDL) particles 
is increased [34]. Similar, the modification of cytokines 
including plasminogen activator inhibitor 1, adiponectin 
or interleukin 6, have been described in the association 
with NAFLD, and more strongly with non-alcoholic ste-
atohepatitis [33]. Also, it has been shown that endothe-
lial dysfunction occurs in experimental studies after a 
few days of high-fat feeding, when steatosis has devel-
oped but inflammation has not [35]. Nevertheless, indi-
rect linkage of NAFLD to cardiovascular disease across 
NAFLD as a player in the development of diabetes and 
the metabolic syndrome must be recognized as well [33]. 
Thus, further study is hence needed to gain mechanistic 
Fig. 3 Subgroup-analysis stratified into subjects with diabetes, prediabetes and normal controls. Boxplots of left ventricular concentricity index 
(LVCI) across tertiles of abdominal visceral adipose tissue (VAT). p value represents a trend-test. (49 diabetes [lower: 2, mid: 10, upper: 37], 99 
prediabetes [lower: 8, mid: 36, upper: 55] and 226 normal controls [lower: 114, mid: 79, upper: 33]
Table 3 Effect of diabetic status in the association of adiposity with LV parameters
The β-coefficients represent change in LV parameters for one standard deviation increment in VAT estimated by linear regression (adjusted for sex, age); the models 
were not fit for the association between VAT and LVM since they were non-significant after adjustment for age and gender (Table 2)
VAT visceral adipose tissue, LV left-ventricular, LVCI left-ventricular concentricity index (mL/g), LVEDV left-ventricular end-diastolic volume (mL/m2), LVSV left ventricular 
stroke volume (mL/m2)
Controls Pre-diabetics Diabetics p value 
inter-
action
β (95% CI) β (95% CI) β (95% CI)
VAT—LVCI 0.11 (0.08; 0.15) 0.10 (0.03; 0.16) 0.16 (0.04; 0.28) 0.74
VAT—LVEDV − 6.59 (− 8.81; − 4.36) − 3.91 (− 7.05; − 0.77) − 4.18 (− 9.7; 1.34) 0.77
VAT—LVSV − 4.03 (− 5.62; − 2.44) − 2.46 (− 4.4; − 0.53) − 3.90 (− 6.86; − 0.94) 0.81
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insight into the pathophysiology of the hepatic steato-
sis and LV structural changes as well as cardiovascular 
disease.
Metabolic connection between abdominal adiposity 
and LV remodeling
It is important to note that our cohort has a relatively lim-
ited size compared to MESA (n = 1151) or Dallas heart 
study (n = 2710). However, due to the nested design, our 
population had a higher percentage of patients with pre-
diabetes (27%) and diabetes (13%) than the other two 
population-based cohorts (in MESA: 9 and 4% and Dal-
las heart study: N/A and 11%; respectively). Despite this 
increased power to detect difference, we did not reveal 
any interaction of the diabetic status on the correlation 
of VAT and LV-parameters even though Shah et al. and 
Canepa et al. [13, 18] suggested a metabolic connection 
between the interactions of VAT and LV parameters. 
Thus, our finding are in line with Rider et  al. [10] who 
described insulin as an exemplary serum marker in dia-
betes for predicting LVM and Neeland et  al. [11] who 
noted that the correlation between VAT and LV are inde-
pendent of adipocytokines and insulin resistance. Also, 
our results add to the hypothesis by Shah et al. [13] that 
insulin resistance serves as a confounder in the interac-
tion of obesity and LV remodeling as the correlation of 
BMI and LV parameters attenuated after multivariable 
adjustment (e.g. waist-to-hip-ratio). We confirm these 
observations by demonstrating that clearly VAT but not 
SAT is associated with subtle LV impairment. Similarly, 
a cardio-metabolic connection for NAFLD has been pos-
tulated by VanWagner et  al. [36] As measured by CT, 
subclinical LV remodeling by echocardiography strain 
analysis from the multicenter, community-based coro-
nary artery risk development in young adults (CARDIA) 
study was associated with LV parameters; however, in 
contrast, our data demonstrate that VAT is much more 
strongly associated with subclinical myocardial dysfunc-
tion as compared to  PDFFhepatic. Clearly, further studies 
are needed to yield a better understanding of the meta-
bolic connection of abdominal adiposity and cardiac 
parameters.
Limitation
Our results do not imply causality because of the cross-
sectional study design and need to be confirmed in 
longitudinal studies. Also, since the KORA cohort is 
single-centered, generalizability and external validity of 
our findings must be confirmed in the future. Because 
of the limited sample size and certain small subgroups 
(e.g. subjects with low VAT but presence of diabetes) 
we might lack statistical power to demonstrate signifi-
cant interaction of diabetes in the association between 
VAT and LV remodeling.
Conclusion
In conclusion, particularly VAT but also fatty liver 
parenchyma are independently and incrementally asso-
ciated with early changes of LV remodeling in a general 
western population without history of cardiovascular 
disease. Although a metabolic connection is suggestive, 
no interaction with the diabetic status was revealed for 
these important associations.
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Appendix
See Tables 4 and 5.
Table 4 Selection of confounders based on univariate analysis
Covariates with a p value < 0.10 were included in multivariate analysis (italicized). In case of co-linearity (*), the more common definition of the risk factors was 
included. Age, sex and BMI were included in the model based on previous literature independent of the p value (PreDef)
LVM LVCI LVEDV LVSV
Age (years) PreDef (0.33) PreDef (< 0.001) PreDef (< 0.001) PreDef (0.001)
Sex (men) PreDef (< 0.001) PreDef (< 0.001) PreDef (0.24) PreDef (0.33)
BMI (kg/m2) PreDef (0.007) PreDef (< 0.001) PreDef (< 0.001) PreDef (< 0.001)
Diabetes status 0.03 < 0.001 < 0.001 < 0.001
HbA1c 0.003* < 0.001* 0.004* < 0.001*
Hypertension < 0.001 < 0.001 0.02 0.08
Systolic RR (mmHg) < 0.001* < 0.001* 0.003* 0.003*
Diastolic RR (mmHg) 0.007* < 0.001* 0.003* < 0.001*
Antihypertensive medication 0.03* 0.001* 0.08* 0.61
Triglyceride levels (mg/dL) < 0.001 < 0.001 0.001 < 0.001
Total cholesterol (mg/L) 0.90 0.003* 0.001* 0.001*
HDL (mg/dL) < 0.001 < 0.001 0.02 < 0.001
LDL (mg/dL) 0.54 0.001 0.001 < 0.001
Lipid lowering medication 0.05 0.02 0.42 0.46
Smoking status 0.30 0.48 0.98 0.99
Table 5 Sensitivity-Analysis of the Multivariate Association Models
The main multivariate analysis included potential confounders, selection was based on univariate analysis as detailed in Appendix Table 4 (a the model included age, 
sex, BMI, hypertension, diabetes, triglycerides, HDL (for all LV parameters), additionally LDL (for LVCI, LVEDV, and LVSV) and lipid lowering medication (for LVM, and 
LVCI)). In the sensitivity analysis, a model with fixed set of typical cardiovascular risk factors as potential confounders were conducted (b the model included age, sex, 
BMI, hypertension, diabetes, smoking). Further, the definition of hypertension was replaced by continuous measurements of systolic and diastolic blood pressure 
and presence if antihypertensive medication (c the fully adjusted model included age, sex, BMI, systolic blood pressure, diastolic blood pressure, antihypertensive 
medication, diabetes, smoking)
LVM LVCI LVEDV LVSV
β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p
Initial analysis (= Table 2): separate,  fullya adjusted models as in the main analysis
 VAT – 0.11 (0.07; 0.15) < 0.001 − 6.70 (− 8.84; − 4.55) < 0.001 − 3.91 (− 5.32; − 2.50) < 0.001
 SAT – – – − 1.75 (− 3.66; 0.16) 0.07
 PDFFhepatic – 0.06 (0.02; 0.09) 0.001 − 3.23 (− 5.03; − 1.44) < 0.001 − 2.20 (− 3.37; − 1.04) < 0.001
Sensitivity analysis 1: separate,  fullyb adjusted models with a fixed set of typical cardiovascular risk factors
 VAT – 0.13 (0.09; 0.16) < 0.001 − 7.04 (− 9.12; − 4.97) < 0.001 − 4.38 (− 5.76; − 3.01) < 0.001
 SAT – – – − 1.66 (− 3.62; 0.29) 0.10
 PDFFhepatic – 0.07 (0.03; 0.10) < 0.001 − 3.54 (− 5.35; − 1.74) < 0.001 − 2.47 (− 3.66; − 1.29) < 0.001
Sensitivity analysis 2: separate,  fullyc adjusted models with a fixed set of typical cardiovascular risk factors and a replacement of the definition of 
hypertension
 VAT – 0.12 (0.08; 0.15) < 0.001 − 6.79 (− 8.88; − 4.7) < 0.001 − 4.22 (− 5.59; − 2.85) < 0.001
 SAT – – – − 1.49 (− 3.41; 0.43) 0.13
 PDFFhepatic – 0.06 (0.02; 0.09) 0.001 − 3.30 (− 5.13; − 1.48) < 0.001 − 2.32 (− 3.51; − 1.14) < 0.001
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